RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Dermapharm Holding Net Income 2024

Dermapharm Holding Net Income

122.24 M EUR

Dermapharm Holding Dividend yield

3.13 %

Ticker

DMP.DE

ISIN

DE000A2GS5D8

WKN

A2GS5D

In 2024, Dermapharm Holding's profit amounted to 122.24 M EUR, a 96% increase from the 62.37 M EUR profit recorded in the previous year.

The Dermapharm Holding Net Income history

YEARNET INCOME (undefined EUR)
2029e-
2028e-
2027e-
2026e138.94
2025e139.32
2024e122.24
202362.37
2022134.24
2021209.58
202085.83
201977.2
201875.32
201720.61
201616.82
201512.7
2014-0.06

Dermapharm Holding Aktienanalyse

What does Dermapharm Holding do?

Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich. Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications. The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products. Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products. Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women. Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils. Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products. Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Dermapharm Holding's Profit Margins

The profit margins of Dermapharm Holding represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Dermapharm Holding's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Dermapharm Holding's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Dermapharm Holding's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Dermapharm Holding’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Dermapharm Holding Stock

How much profit has Dermapharm Holding made this year?

Dermapharm Holding has made 122.24 M EUR this year.

How has the profit developed compared to last year?

The profit has increased by 96% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Dermapharm Holding publish its earnings?

Dermapharm Holding publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Dermapharm Holding?

The profits of Dermapharm Holding are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Dermapharm Holding?

You can learn more about the earnings of Dermapharm Holding by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Dermapharm Holding pay?

Over the past 12 months, Dermapharm Holding paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 3.13 %. For the coming 12 months, Dermapharm Holding is expected to pay a dividend of 1.14 EUR.

What is the dividend yield of Dermapharm Holding?

The current dividend yield of Dermapharm Holding is 3.13 %.

When does Dermapharm Holding pay dividends?

Dermapharm Holding pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Dermapharm Holding?

Dermapharm Holding paid dividends every year for the past 0 years.

What is the dividend of Dermapharm Holding?

For the upcoming 12 months, dividends amounting to 1.14 EUR are expected. This corresponds to a dividend yield of 3.41 %.

In which sector is Dermapharm Holding located?

Dermapharm Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dermapharm Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dermapharm Holding from 7/2/2024 amounting to 0.88 EUR, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Dermapharm Holding pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Dermapharm Holding in the year 2023?

In the year 2023, Dermapharm Holding distributed 2.17 EUR as dividends.

In which currency does Dermapharm Holding pay out the dividend?

The dividends of Dermapharm Holding are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dermapharm Holding stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital

Andere Kennzahlen von Dermapharm Holding

Our stock analysis for Dermapharm Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dermapharm Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.